JMP reiterates Indevus at strong buy

JMP Securities analyst Adam Cutler reiterated Indevus Pharmaceuticals, Inc. at strong buy on news the pagoclone phase 3 trial for stuttering to start in the first half of 2007. The trial will likely include six months of treatment and co-primary endpoints of the severity and duration measures of the SSI-3 and CGI scale. Pagoclone showed a statistically significant improvement in both of these endpoints in an eight-week phase 2 trial. Shares of the Lexington, Mass.-based biopharmaceutical company were down 6 cents, or 1.00%, at $5.95. (Nasdaq: IDEV)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.